The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Braveheart Investment Group (AIM: BRH), is pleased to announce a further investment into Phasefocus Holdings Limited ("Phasefocus"). The Company has purchased 18,750 new ordinary shares of one pence each in Phasefocus at a price of £8 per share for a total consideration of £150,000, taking Braveheart's total interest to 48.3 per cent. of the issued share capital of Phasefocus.
Phasefocus' imaging and analysis system, Livecyte®, uses a novel patented method for high fidelity quantitative imaging and microscopy; this is known in the scientific literature as 'ptychography'.
As announced on 31 May 2023, Phasefocus has gained substantial momentum during the year and its work, in particular with distributors in Japan, China and the USA, has built a strong pipeline of business opportunities. Phasefocus has received a number of orders for its Livecyte® system, which are scheduled to be delivered before the end of 2023.
On 14 August 2023, Phasefocus announced the launch of its revolutionary new T-Cell Killing Assay for the Livecyte® cell imaging platform https://www.phasefocus.com/about/news-events/news/t-cell-assay-announcement. The new assay quantifies interactions between immune cells and cancer cells, addressing a major unmet need for researchers developing the latest novel cancer therapies. In the assay, the characteristics of T cell interactions in the period immediately preceding target cell death, can be measured independently from cytotoxicity. Livecyte's T-Cell Killing Assay offers unparalleled insights at the single-cell level, empowering researchers to unlock new frontiers in cancer therapy development and evaluation.
This investment by Braveheart will provide Phasefocus with the working capital to market its new T-Cell Killing Assay and build Livecyte® stock, in preparation for further anticipated orders, and follows a £134,000 investment by the Company into Phasefocus in January 2023.
In the year ended 31 December 2022, Phasefocus incurred a loss before taxation of £990,854. The book value of Braveheart's investment in Phasefocus at 31 March 2023 (prior to this investment) was £2.5 million.
Share this article
Half-year Report
BRAVEHEART INVESTMENT GROUP PLC
Released 07:00:06 28 October 2022
RNS Number : 4170E
Braveheart Investment Group plc
28 October 2022
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
28 October 2022
Braveheart Investment Group plc
("Braveheart" or the "Company" or the "Group")
Interim Results
Braveheart Investment Group plc (AIM: BRH), announces its interim results for the six months ended 30 September 2022.
Highlights:
· Income of £36,000 in the six months ended 30 September 2022 (H1 2021: £3,364,000);
· Loss of £761,000 in the six months ended 30 September 2022 (H1 2021: £2,533,000);
· Loss per share of 1.19p in the six months ended 30 September 2022 (H1 2021: 4.85p);
· Investments into Aukett S****e Group plc and PhaseFocus Holdings Limited
· Funds raised in the period totalling £965,000 (before expenses)
Post Period End
· Aukett S****e Group plc shareholding increased to 19.37%
· Autins Group plc shareholding increased to 12.91%
For further information:
Braveheart Investment Group plc (AIM: BRH), provides the following update on its investment portfolio and strategy.
The UK Government's decision to rapidly wind down the testing and isolation requirements for UK citizens and travellers to the UK has abruptly changed the nature of the COVID-19 test market which has led to a slowing of discussions with the remaining potential acquirers of Paraytec Limited and its COVID-19 test. It now appears unlikely that Braveheart will be able to conclude a sale with one of the remaining engaged parties at an acceptable price in the foreseeable future.
Braveheart's board believes that after the completion of the prospective clinical study, scheduled to be concluded by the end of June 2022 and provide clinical proof of concept of the CX300 technology platform, it would be in the best interests of shareholders that Paraytec focus on the development of the sepsis and bladder cancer applications for its technology. Paraytec believes the development of the COVID test to date will be invaluable for the development of sepsis, bladder cancer and other applications of the CX300 technology platform. Since the remaining potential partners and potential acquirers that Braveheart is in discussions with are interested in both the COVID and sepsis applications, it may be that a buyer or partner will still emerge in due course.
Braveheart's remaining strategic investments are well positioned for growth and we will continue to adopt a dual strategy of building their value and at the same time engaging in discussions with potential acquirers, thereby seeking to maximise value to Braveheart
Braveheart's current share price has fallen in recent weeks, largely in response to a change in market sentiment towards 'COVID companies', which has impacted other quoted companies in this space. However, the Board believes that while the current share price is now close to the net asset value stated in the unaudited Interim Accounts, Paraytec, though an important component of shareholder value within the Group will not on its own, determine the prospects for increasing shareholder returns.
Your Board remains committed to generating shareholder value in the short and medium term, through its strategy of investing in and developing undervalued technology businesses and will update shareholders as events unfold.
21-Dec-21 15:10:59 21.90 1,000 Sell* 21.50 22.50 21.90k O
21-Dec-21 15:09:23 21.90 77 Buy* 21.00 22.50 1,686 O
21-Dec-21 15:05:11 21.90 985 Buy* 21.00 22.50 21.57k O
21-Dec-21 15:02:29 21.87 6,378 Buy* 21.00 22.50 139.49k O
21-Dec-21 15:01:58 21.90 4,543 Buy* 21.00 22.50 99.49k O
21-Dec-21 14:53:54 21.87 18,013 Buy* 21.00 22.50 393.94k O
21-Dec-21 14:52:52 21.90 456 Buy* 21.00 22.50 9,986 O
21-Dec-21 14:51:52 21.515 10 Sell* 21.00 22.50 215.15 O
21-Dec-21 14:51:22 21.515 662 Sell* 21.00 22.50 14.24k O
21-Dec-21 14:49:27 22.00 50,000 Buy* 21.00 22.00 1m O
21-Dec-21 14:48:49 21.507 15,000 Buy* 21.00 22.00 322.61k O
21-Dec-21 14:48:46 21.735 1,000 Buy* 21.00 22.00 21.74k O
21-Dec-21 14:48:35 21.74 459 Buy* 21.00 22.00 9,979 O
21-Dec-21 14:46:53 21.735 4,278 Buy* 21.00 22.00 92.98k O
21-Dec-21 14:45:07 21.5055 222 Buy* 21.00 22.00 4,774 O
21-Dec-21 14:43:17 21.73 10,000 Buy* 21.00 22.00 217.30k O
21-Dec-21 14:42:33 21.505 65,800 Buy* 21.00 22.00 1m O
21-Dec-21 14:40:52 21.505 10,000 Buy* 21.00 22.00 215.05k O
21-Dec-21 14:39:37 21.50 2,043 Unknown* 21.00 22.00 43.92k O
21-Dec-21 14:39:36 21.50 5,000 Unknown* 21.00 22.00 107.50k
Oracle Power PLC
("Oracle", the "Company" or the "Group")
Green Hydrogen Co-Operation Agreement with PowerChina International Group Ltd
Oracle Power PLC (AIM:ORCP), the international natural resources project developer, is pleased to announce that it has signed a non-exclusive co-operation agreement (the "Agreement") with PowerChina International Group Ltd ("PowerChina") with the objective of jointly developing a green hydrogen production facility in ****stan.
Highlights
· Green hydrogen, hydrogen that is generated from renewable sources, is widely regarded as one of the most important energy sources to support the transition to a carbon neutral future
· Green hydrogen is becoming a competitive fuel source in multiple sectors, including steel and fertiliser production, cars, power generation, long-range shipping and aviation
· PowerChina, one of the largest Chinese state-owned-enterprises, has partnered with Oracle, with the intention to set up a hydrogen facility in ****stan to produce hydrogen with electrolysers powered by photovoltaics
· Targeting a 400MW capacity hydrogen plant, with planned hydrogen production of approximately 150,000 kg per day
· The Government of ****stan is reviewing proposals from international investors and has also set up a dedicated team to review options and strategy
· PowerChina has reported its interest to its government in China and the project is expected to receive bilateral support through the CPEC programme
· PowerChina is working on a technical pre-feasibility and both parties have begun collaborating with their respective governments for required support.
Naheed Memon, CEO of Oracle, commented:
"Green hydrogen is potentially the single most important tool the international community has in our collective bid to transition to a carbon neutral future. I am delighted to announce our agreement with PowerChina as we explore options of jointly developing a green hydrogen facility in ****stan, which would represent the first production facility of its kind in the country and could support multiple industries including steel and fertiliser production, power generation, shipping and the aviation industry.
"Green hydrogen is already high on the agenda for many countries, including India and many of the Gulf nations, however this agreement would make Oracle a first mover in ****stan, a jurisdiction which has abundant renewable resource and land available. I am delighted that we have entered into an agreement with PowerChina, given PowerChina's position and experience in the field of energy and power development and contracting. We jointly plan to set up a 400MW capacity hydrogen plant to produce approximately 150,000 kg of green hydrogen per day.
"I believe that green hydrogen would provide a highly valuable additional pillar to our portfolio of assets, which now includes our two highly prospective gold proper
at close 5 mms on the buy at 45 1 on the sell at 48 . and 6 on the sell at 50 . the mms are loading up as they are anticipating a big rerate . any good news and this will fly north of £1 .50 and prob easily go into £2 bracket . ..... tho i anticipate it will go much higher with another large dividend pay out gla
wot ever ........ when the children on this board stop bickering amonst themselves it will give us all a break having to read total bolooooks posts . either put your money in and buy and hold or just fold . me i am going to buy another 5 million shares when my russian mine sells soon ..
The Company intends to fund the initial cash component of the transaction from an investment of fresh capital being finalised with a group of new institutional investors.
Given the transaction and forward movement of the Company, SYME will be expanding its Board of Directors to bring in additional banking and legal experience, including the appointment, after completion and pursuant to the Company' nomination procedures, of Mr Tom James and Mr John Collis, the Co-Founders and Directors of TradeFlow, who will be key members of the combined business.. for all the naysayers out there . please explain to me : -- why would trade flow valued at £31 mill sell for £4 mill plus shares and become board members if they had not seen the potential with joining forces with syme . do you think the investors would put £4 mill into this if they also would not have done due diligence !! . syme is a basically a totally new concept in raising finance especially now in our covid world where banks will be reluctant to offer loans .. plus its sharia compliant which under muslim law you cannot pay interest on a loan .. i admit i am invested heavily in this share because i think if you believe in a concept getting in early will / can have massive rewards . . i believe in the board and like the way syme keep adding new skilled members to the team . worry not about daily share machinations. think about where it could be in a couple of years ..unicorn in the making im gambling on as all penny shares are .. gla
2 years ago i was a total newby to investing in the stock market . i had very little cash so it was just punt money . £3k in oil companies my mentor had advised me to get into . those companies didnt produce any decent returns at the the time however i decided to spend more time looking for other stocks to buy into . i decided that if 1 company out of 10 with another £10 k invested came good it would negate any losses . so here i am with eua . an initial buy at 3p for £2k s worth . sold half when it went to 7p . i originally thought the company could easily do £1 after much research . since then i have invested another prob £15 k into this share from 23p to 40 p . i only have 140000 shares but think i invested wisely . we as share holders have a much more valueable asset with the jv . its probably worth prob £2 a share now . the world has gone mad for rare minerals which we have an abundance of . also we have a brilliant board of directors who will look after us re the sale whether it be a full sale of assets or partial sale with dividend payments . . not long now .. i am now looking for my next big return investment but with a lot more cash to fund it .. gla
my thorts . a muslim is not allowed to pay any interest on a loan . approx 25% of the worlds population is muslim . syme business model is not a loan so complies with sharia laws meaning syme as a company supplying finance to sharia companies may be ahead of any competitors . if as i believe this to an accurate analasis this company is a unicorn in this market alone . sit back , strap yourselves in and 1 day rodney we will be millionaires
i bought into this share prob 18 months ago at around 3p . i thought then that it could be worth £1 minimum . since then the world has gone crazy for ev cars etc . there are no flooding problems as it is open cast . no electricity probs . now with the jv secured i value it at £2 hold your nerve and all will be rewarded whether it be a full sale or partial sale with dividends gla